Sunday, June 25th, 2018
Halifax Convention Centre, Halifax, NS




Fred Saad, MD, FRCSC (Chair)
Rob Hamilton, MD, MPH, FRCSC
Ricardo Rendon, MD, FRCSC
Alan So, MD, FRCSC


By the end of this program participants will able to discuss the implications of the evolving treatment landscape for patients with hormone-naïve metastatic prostate cancer and castration-resistant prostate cancer, and consider strategies:

  • to evaluate, stratify and follow patients with hormone-sensitive and castration-resistant prostate cancer
  • to recognize disease progression, timing of therapy change, and optimal referral to radiation and medical oncology
  • to optimize treatment options for the different states of advanced prostate cancer

This event wasan Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Canadian Urological Association. Participants were able to claim a maximum of 1 hour of credit.

This program has received support from Janssen Inc. in the form of an educational grant

Mobile Login Form

Login to view videos. Members - Contact for your password | Meeting participants contact